BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 23/04/2018

FDA Announces Draft Guidance for Developing Depot Buprenorphine Products for Opioid Dependence Treatment

The FDA has released a draft guidance document outlining the agency's expectations for developing and testing depot buprenorphine products for the treatment of opioid dependence.

Source: Federal Register — Food and Drug AdministrationOpen original release →